Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2019 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
MIRM on Nasdaq
Shares outstanding
51,368,292
Price per share
$78.99
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
57,250,652
Total reported value
$4,197,044,283
% of total 13F portfolios
0.01%
Share change
+1,595,658
Value change
+$132,883,007
Number of holders
267
Price from insider filings
$78.99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 11% +6% $388,340,181 +$31,912,348 5,445,039 +9% JANUS HENDERSON GROUP PLC 28 Nov 2025
Frazier Life Sciences IX, L.P. 7.4% 0% $273,828,978 3,735,220 0% James N. Topper 01 Nov 2025
EVENTIDE ASSET MANAGEMENT, LLC 5.4% $103,182,606 2,606,938 Eventide Asset Management, LLC 31 Dec 2024
BIOTECHNOLOGY VALUE FUND L P 3% $109,619,710 1,495,290 BVF PARTNERS L P/IL 30 Sep 2025

As of 30 Sep 2025, 267 institutional investors reported holding 57,250,652 shares of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM). This represents 111% of the company’s total 51,368,292 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) together control 75% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 13% 6,795,121 0% 15% $498,150,321
JANUS HENDERSON GROUP PLC 9.7% 4,997,586 -4.6% 0.17% $366,518,621
BlackRock, Inc. 7% 3,602,434 +0.71% 0% $264,094,437
VANGUARD GROUP INC 5% 2,545,369 -0.76% 0% $186,601,001
EVENTIDE ASSET MANAGEMENT, LLC 4.9% 2,522,563 -4.4% 3% $184,923,401
BVF INC/IL 2.9% 1,495,290 -46% 4.4% $109,619,710
STATE STREET CORP 2.6% 1,346,904 -2.1% 0% $98,741,532
PRICE T ROWE ASSOCIATES INC /MD/ 2.5% 1,283,288 -9.5% 0.01% $94,079,000
NOVO HOLDINGS A/S 2.5% 1,264,028 -16% 6% $92,665,893
TANG CAPITAL MANAGEMENT LLC 2.4% 1,236,027 0% 3.5% $90,613,139
CITADEL ADVISORS LLC 2% 1,040,544 -26% 0.06% $76,282,281
GEODE CAPITAL MANAGEMENT, LLC 2% 1,010,022 -1.9% 0% $74,056,868
Clearbridge Investments, LLC 2% 1,003,803 -2.3% 0.06% $73,588,785
D. E. Shaw & Co., Inc. 1.8% 923,509 +66% 0.05% $67,702,445
Polar Capital Holdings Plc 1.6% 820,552 -16% 0.29% $60,154,667
WELLINGTON MANAGEMENT GROUP LLP 1.5% 790,689 +567% 0.01% $57,965,410
Point72 Asset Management, L.P. 1.5% 790,675 +205% 0.13% $57,964,420
Rock Springs Capital Management LP 1.5% 761,126 -7% 3.3% $55,798,147
MORGAN STANLEY 1.3% 670,149 +18% 0% $49,128,631
LORD, ABBETT & CO. LLC 1.3% 661,940 -14% 0.14% $48,527,000
FMR LLC 1.2% 640,218 +977% 0% $46,934,414
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.2% 612,318 +709% 0.03% $44,889,033
Nuveen, LLC 1.2% 601,670 +1.9% 0.01% $44,108,428
FRANKLIN RESOURCES INC 1.2% 601,137 +1.3% 0.01% $44,069,353
BNP PARIBAS FINANCIAL MARKETS 1.2% 601,073 0% 0.03% $44,064,662

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 36,026 $2,823,194 +$1,603,069 $78.99 11
2025 Q3 57,250,652 $4,197,044,283 +$132,883,007 $73.31 267
2025 Q2 55,393,376 $2,819,026,675 +$70,442,433 $50.89 212
2025 Q1 54,142,705 $2,443,758,825 +$49,081,183 $45.05 213
2024 Q4 53,012,279 $2,191,982,974 -$15,285,717 $41.35 204
2024 Q3 53,053,452 $2,069,573,414 -$12,694,355 $39.00 178
2024 Q2 53,366,025 $1,824,581,927 +$11,904,127 $34.19 160
2024 Q1 53,243,448 $1,337,601,646 +$67,547,049 $25.12 169
2023 Q4 253,382 $7,493,037 -$2,048,222 $29.52 3
2023 Q3 48,705,333 $1,538,482,736 +$386,533,948 $31.60 157
2023 Q2 36,937,639 $955,518,380 +$63,103,380 $25.87 143
2023 Q1 34,669,406 $832,753,937 +$33,993,013 $24.02 114
2022 Q4 33,331,988 $650,146,662 -$11,846,583 $19.50 101
2022 Q3 31,984,470 $672,023,633 +$84,150,814 $21.01 105
2022 Q2 29,128,665 $565,309,366 +$45,714,634 $19.46 100
2022 Q1 26,800,065 $590,144,915 +$50,846,120 $22.02 98
2021 Q4 24,771,073 $395,072,000 +$18,686,633 $15.95 80
2021 Q3 21,403,967 $426,314,254 +$2,760,942 $19.92 69
2021 Q2 21,481,792 $371,408,185 +$679,329 $17.29 65
2021 Q1 23,373,102 $425,212,077 -$8,433,489 $19.82 61
2020 Q4 22,010,623 $384,380,000 +$52,268,028 $17.46 71
2020 Q3 18,743,135 $361,180,000 -$1,291,555 $19.27 50
2020 Q2 18,802,014 $365,890,000 +$8,882,637 $19.46 56
2020 Q1 18,603,225 $260,445,000 +$32,083,306 $14.00 43
2019 Q4 16,248,910 $398,421,000 +$12,821,717 $24.52 39
2019 Q3 16,482,479 $165,808,000 +$165,706,985 $10.06 37